MR vaccine

MR vaccine
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽

The MR vaccine is a vaccine that protects against measles and rubella.[1] Two doses are usually given at least one month apart.[2] In countries where measles cases are higher, the first dose is recommended at 9 months of age.[2] In other countries it is typically offered between 12 and 15 months of age.[2] In children at high risk of severe measles, the vaccine can be given at 6 months of age with a second dose at 9 months.[2] It is given by injection under the skin.[3]

Side effects are generally mild, temporary and except for allergic reaction are less likely after the second dose.[2] Redness, swelling and pain can occur at the site of injection.[2] A fever may occur typicallybetween 7 and 12 days after a dose.[2] Between 7 and 10 days after a dose, a rash may appear, typically lasting around 2 days.[2] Rare side effects include bruising due to low platelets and an allergic reaction.[2] The vaccine is not recommended in pregnancy, but if inadvertently given, has not been shown to cause harm to the baby.[2] If planning a pregnancy, then it is best to wait at least a month after a dose.[2] It is not safe to give to people with a severely weakened immune system.[2]

Mumps has not been targeted for global elimination, and the MR vaccine is preferred in countries where mumps is not a priority.[1] The MR vaccine was introduced in India in 2017 as part of a mass campaign to eliminate measles and CRS caused by rubella.[4] Around 150 million doses of an Indian-made MR vaccine are available globally, except in Europe.[1] Until given, the vaccine should be kept cold but not frozen.[2]

References

  1. 1 2 3 Vesikari, Timo; Usonis, Vytautas (2021). "9. Measles-Mumps-Rubella vaccine". In Vesikari, Timo; Damme, Pierre Van (eds.). Pediatric Vaccines and Vaccinations: A European Textbook (Second ed.). Switzerland: Springer. p. 83. ISBN 978-3-030-77172-0. Archived from the original on 2022-02-02. Retrieved 2022-02-02.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 Model insert: Measles and Rubella (MR) combined vaccine (PDF). World Health Organization. December 2005. Archived (PDF) from the original on 2022-01-19. Retrieved 2022-02-02.
  3. "Serum Institute Of India - MR-Vac - Measles & Rubella Vaccine (Live) I.P." www.seruminstitute.com. Archived from the original on 20 April 2021. Retrieved 2 February 2022.
  4. "India's measles-rubella vaccination campaign a big step towards reducing childhood mortality, addressing birth defects". www.who.int. Archived from the original on 3 February 2022. Retrieved 3 February 2022.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.